Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of hard-to-treat disease in a unique and transformative approach to drug discovery and development. Alchemab takes an unbiased and function-first approach using three complementary processes and cutting-edge technologies to identify naturally protective antibodies. Alchemab’s engine is enabled through collaborations with patient representative groups and biobanks around the world with whom we partner to further our understanding of disease.
View Top Employees from Alchemab Therapeutics Ltd| Website | http://www.alchemab.com |
| Funding | $82 million |
| Employees | 67 (56 on RocketReach) |
| Founded | 2019 |
| Technologies |
JavaScript,
HTML,
PHP
+26 more
(view full list)
|
| Industry | Biotechnology Research, Drug Manufacturing & Research, Biotechnology, Pharmaceuticals, Drug Discovery, Healthcare |
| SIC | SIC Code 2833 Companies, SIC Code 28 Companies, SIC Code 283 Companies, SIC Code 2834 Companies |
| NAICS | NAICS Code 54138 Companies, NAICS Code 541 Companies, NAICS Code 5413 Companies, NAICS Code 54 Companies |
Looking for a particular Alchemab Therapeutics Ltd employee's phone or email?
Alchemab Therapeutics Ltd Questions
Young Kwon is the CEO of Alchemab Therapeutics Ltd.
56 people are employed at Alchemab Therapeutics Ltd.
The NAICS codes for Alchemab Therapeutics Ltd are [54138, 541, 5413, 54].
The SIC codes for Alchemab Therapeutics Ltd are [2833, 28, 283, 2834].
Top Alchemab Therapeutics Ltd Employees
-
55+
-
11
-
11
-
ViewOlivia Cavlan
Chief Corporate Development and Strategy Officer at Alchemab Therapeutics Ltd
London, England, United Kingdom5+3
Related Companies
